Seeing Is Believing
Currently out of the existing stock ratings of Paul Matteis, 163 are a BUY (66.26%), 83 are a HOLD (33.74%).
Analyst Paul Matteis works at STIFEL with a stock forecast success ratio of 55.07% fulfilled within 188.26 days on average.
Paul Matteis’s has documented 504 price targets and ratings displayed on 36 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 18-Dec-2023.
Analyst best performing recommendations are on AVDL (AVADEL PHARMACEUTICALS PLC).
The best stock recommendation documented was for AVDL (AVADEL PHARMACEUTICALS PLC) at 5/26/2022. The price target of $2 was fulfilled within 1 day with a profit of $0.93 (86.92%) receiving and performance score of 869.16.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
25
$7.16 (40.13%)
29
2 days ago
5/8 (62.5%)
$7.16 (40.13%)
26
Buy
30
$12.16 (68.16%)
40
14 days ago
16/19 (84.21%)
$10.44 (53.37%)
184
Buy
39
$21.16 (118.61%)
40
28 days ago
6/10 (60%)
$15.25 (64.21%)
94
Buy
33
$15.16 (84.98%)
33
28 days ago
8/19 (42.11%)
$9.25 (38.95%)
119
Buy
36
$18.16 (101.79%)
28 days ago
0/1 (0%)
$12.25 (51.58%)
Which stock is Paul Matteis is most bullish on?
Which stock is Paul Matteis is most reserved on?
What Year was the first public recommendation made by Paul Matteis?